News | February 15, 2012

Vessix Vascular Presents V2 Renal Denervation System for Hypertension

February 15, 2012 — Vessix Vascular Inc., developer of a novel percutaneous radiofrequency (RF) balloon catheter technology, announced that it will make its first detailed public presentation of preclinical data relating to its new V2 Renal Denervation System on Saturday, Feb. 18, 2012 at the TRenD Workshop 2012, in Frankfurt, Germany.

The presentation, titled "Percutaneous RF balloon-mediated renal denervation in under a minute: The V2 System by Vessix," will be made by James R. Margolis, M.D., during a session focused on emerging technologies for renal denervation.

Renal denervation is a percutaneous, catheter-based approach that disrupts renal sympathetic nerves whose hyperactivity leads to uncontrolled high blood pressure.

Margolis commented, "Vessix's pre-clinical data is the most robust I have seen in the field of renal denervation for hypertension. The data provides significant angiographic and histological evidence of safety and also effectiveness in reducing kidney norepinephrine levels – a surrogate for reduction of blood pressure in humans. The Vessix RF balloon catheter technology promises to place a very familiar tool in the hands of interventionalists and allow therapy to be safely delivered in seconds. I look forward to seeing the results of the upcoming multi-center international clinical study set to begin in Europe later this month."

Vessix's V2 Renal Denervation System for the treatment of drug resistant hypertension is an over the wire balloon catheter with electrodes mounted on the exterior of the balloon to facilitate the delivery of RF inside the renal artery. The patented catheter connects to a proprietary low power bipolar RF generator. After inflation in the artery, the balloon catheter's RF energy is activated for 30 seconds resulting in the disruption of the renal nerves located in the adventitia that surround the renal artery.

For more information:

Related Content

CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
Overlay Init